Regeneron Pharmaceuticals, Inc.
(NASDAQ : REGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.24%349.230.0%$6645.11m
BNTXBioNTech SE 3.67%340.390.0%$1133.09m
SNSSSunesis Pharmaceuticals, Inc. 3.80%10.920.7%$763.35m
NVAXNovavax, Inc. 3.28%185.2179.8%$670.32m
AMGNAmgen, Inc. -0.37%240.641.3%$497.38m
BIIBBiogen, Inc. 1.87%332.841.7%$439.32m
VRTXVertex Pharmaceuticals, Inc. -1.61%198.341.9%$408.06m
GILDGilead Sciences, Inc. 0.00%68.291.0%$401.30m
REGNRegeneron Pharmaceuticals, Inc. 0.44%577.162.7%$355.46m
ILMNIllumina, Inc. -0.14%495.073.5%$263.65m
NTLAIntellia Therapeutics, Inc. -2.21%138.722.3%$258.07m
CRSPCRISPR Therapeutics AG 1.82%123.220.6%$147.36m
EXASEXACT Sciences Corp. 1.83%109.8118.1%$125.85m
SGENSeagen Inc. 0.86%154.715.8%$121.26m
XBIOXenetic Biosciences, Inc. 16.22%4.730.0%$118.75m

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.